Current Report Filing (8-k)
June 07 2021 - 8:01AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 2, 2021
YUMANITY THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-37695
|
|
20-8436652
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
40 Guest Street, Suite 4410
Boston, MA
|
|
02135
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: 617-409-5300
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.001 per share
|
|
YMTX
|
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of
1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☒
Item 5.02.
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
As previously disclosed, on June 2, 2021, N. Anthony Coles transitioned to the
role of non-executive Chair of the Board of Directors of Yumanity Therapeutics, Inc. (the Company).
Item 5.07.
|
Submission of Matters to a Vote of Security Holders
|
On June 2, 2021, the Company held its previously announced 2021 Annual Meeting of Stockholders (the Annual Meeting), at which a quorum was
present. The proposals voted on at the Annual Meeting and the final voting results for each proposal are as follows:
1. The Companys stockholders
elected the three director nominees listed below to serve as Class III directors until the Companys 2024 annual meeting of stockholders, with the votes cast as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Director Nominee
|
|
Votes For
|
|
|
Votes Against
|
|
|
Abstentions
|
|
|
Broker Non-Votes
|
|
N. Anthony Coles, M.D.
|
|
|
4,782,090
|
|
|
|
1,367,114
|
|
|
|
4,793
|
|
|
|
1,350,457
|
|
Kim C. Drapkin
|
|
|
5,972,135
|
|
|
|
176,601
|
|
|
|
5,261
|
|
|
|
1,350,457
|
|
Lynne Zydowsky, Ph.D.
|
|
|
6,130,110
|
|
|
|
18,630
|
|
|
|
5,257
|
|
|
|
1,350,457
|
|
2. The Companys stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Companys independent
registered public accounting firm for the fiscal year ending December 31, 2021, with the votes cast as follows:
|
|
|
|
|
|
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
7,481,347
|
|
12,310
|
|
10,797
|
|
0
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
Yumanity Therapeutics, Inc.
|
|
|
|
|
Date: June 7, 2021
|
|
|
|
By:
|
|
/s/ Richard Peters
|
|
|
|
|
|
|
Richard Peters
|
|
|
|
|
|
|
President and Chief Executive Officer
|
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Yumanity Therapeutics (NASDAQ:YMTX)
Historical Stock Chart
From Jul 2023 to Jul 2024